Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research
Published in: Breast Cancer Research 1/2015

Open Access 01-12-2015 | Review

Molecular drivers of lobular carcinoma in situ

Authors: Greg J. Logan, David J. Dabbs, Peter C. Lucas, Rachel C. Jankowitz, Daniel D. Brown, Beth Z. Clark, Steffi Oesterreich, Priscilla F. McAuliffe

Published in: Breast Cancer Research | Issue 1/2015

Login to get access

Abstract

Lobular carcinoma in situ (LCIS) is considered to be a risk factor for the development of invasive breast carcinoma, but it may also be a non-obligate precursor to invasive lobular carcinoma (ILC). Many LCIS lesions do not progress to ILC, and the molecular changes that are necessary for progression from LCIS to ILC are poorly understood. Disruption in the E-cadherin complex is the hallmark of lobular lesions, but other signaling molecules, such as PIK3CA and c-src, are consistently altered in LCIS. This review focuses on the molecular drivers of lobular carcinoma, a more complete understanding of which may give perspective on which LCIS lesions progress, and which will not, thus having immense clinical implications.
Literature
1.
Degnim AC, King TA. Surgical management of high-risk breast lesions. Surg Clin North Am. 2013;93:329–40.PubMedCrossRef
2.
Li CI, Daling JR, Malone KE. Age-specific incidence rates of in situ breast carcinomas by histologic type, 1980 to 2001. Cancer Epidemiol Biomarkers Prev. 2005;14:1008–11.PubMedCrossRef
3.
Page DL, Kidd Jr TE, Dupont WD, Simpson JF, Rogers LW. Lobular neoplasia of the breast: higher risk for subsequent invasive cancer predicted by more extensive disease. Hum Pathol. 1991;22:1232–9.PubMedCrossRef
4.
Bodian CA, Perzin KH, Lattes R. Lobular neoplasia. Long term risk of breast cancer and relation to other factors. Cancer. 1996;78:1024–34.PubMedCrossRef
5.
To T, Wall C, Baines CJ, Miller AB. Is carcinoma in situ a precursor lesion of invasive breast cancer? Int J Cancer. 2014;135:1646–52.PubMedCrossRef
6.
Wellings SR. A hypothesis of the origin of human breast cancer from the terminal ductal lobular unit. Pathol Res Pract. 1980;166:515–35.PubMedCrossRef
7.
Wellings SR, Jensen HM, Marcum RG. An atlas of subgross pathology of the human breast with special reference to possible precancerous lesions. J Natl Cancer Inst. 1975;55:231–73.PubMed
8.
Jensen HM, Rice JR, Wellings SR. Preneoplastic lesions in the human breast. Science. 1976;191:295–7.PubMedCrossRef
9.
Lu YJ, Osin P, Lakhani SR, Di Palma S, Gusterson BA, Shipley JM. Comparative genomic hybridization analysis of lobular carcinoma in situ and atypical lobular hyperplasia and potential roles for gains and losses of genetic material in breast neoplasia. Cancer Res. 1998;58:4721–7.PubMed
10.
Gomes DS, Porto SS, Balabram D, Gobbi H. Inter-observer variability between general pathologists and a specialist in breast pathology in the diagnosis of lobular neoplasia, columnar cell lesions, atypical ductal hyperplasia and ductal carcinoma in situ of the breast. Diagn Pathol. 2014;9:121.PubMedPubMedCentralCrossRef
11.
Dabbs DJ, Schnitt SJ, Geyer FC, Weigelt B, Baehner FL, Decker T, et al. Lobular neoplasia of the breast revisited with emphasis on the role of E-cadherin immunohistochemistry. Am J Surg Pathol. 2013;37:e1–11.PubMedCrossRef
12.
13.
McDivitt RW, Hutter RV, Foote Jr FW, Stewart FW. In situ lobular carcinoma. A prospective follow-up study indicating cumulative patient risks. JAMA. 1967;201:82–6.PubMedCrossRef
14.
Haagensen CD, Lane N, Lattes R, Bodian C. Lobular neoplasia (so-called lobular carcinoma in situ) of the breast. Cancer. 1978;42:737–69.PubMedCrossRef
15.
Rosen PP, Kosloff C, Lieberman PH, Adair F, Braun Jr DW. Lobular carcinoma in situ of the breast. Detailed analysis of 99 patients with average follow-up of 24 years. Am J Surg Pathol. 1978;2:225–51.PubMedCrossRef
16.
17.
Page DL, Schuyler PA, Dupont WD, Jensen RA, Plummer Jr WD, Simpson JF. Atypical lobular hyperplasia as a unilateral predictor of breast cancer risk: a retrospective cohort study. Lancet. 2003;361:125–9.PubMedCrossRef
18.
Marshall LM, Hunter DJ, Connolly JL, Schnitt SJ, Byrne C, London SJ, et al. Risk of breast cancer associated with atypical hyperplasia of lobular and ductal types. Cancer Epidemiol Biomarkers Prev. 1997;6:297–301.PubMed
19.
Ottesen GL, Graversen HP, Blichert-Toft M, Christensen IJ, Andersen JA. Carcinoma in situ of the female breast. 10 year follow-up results of a prospective nationwide study. Breast Cancer Res Treat. 2000;62:197–210.PubMedCrossRef
20.
Hwang ES, Nyante SJ, Yi Chen Y, Moore D, DeVries S, Korkola JE, et al. Clonality of lobular carcinoma in situ and synchronous invasive lobular carcinoma. Cancer. 2004;100:2562–72.PubMedCrossRef
21.
Morandi L, Marucci G, Foschini MP, Cattani MG, Pession A, Riva C, et al. Genetic similarities and differences between lobular in situ neoplasia (LN) and invasive lobular carcinoma of the breast. Virchows Arch. 2006;449:14–23.PubMedCrossRef
22.
Andrade VP, Ostrovnaya I, Seshan VE, Morrogh M, Giri D, Olvera N, et al. Clonal relatedness between lobular carcinoma in situ and synchronous malignant lesions. Breast Cancer Res. 2012;14:R103.PubMedPubMedCentralCrossRef
23.
Aulmann S, Penzel R, Longerich T, Funke B, Schirmacher P, Sinn HP. Clonality of lobular carcinoma in situ (LCIS) and metachronous invasive breast cancer. Breast Cancer Res Treat. 2008;107:331–5.PubMedCrossRef
24.
Wallace AS, Xiang D, Hockman L, Arya M, Jeffress J, Wang Z, et al. Synchronous lobular carcinoma in situ and invasive lobular cancer: marker or precursor for invasive lobular carcinoma. Eur J Surg Oncol. 2014;40:1245–9.PubMedCrossRef
25.
Visvanathan K, Hurley P, Bantug E, Brown P, Col NF, Cuzick J, et al. Use of pharmacologic interventions for breast cancer risk reduction: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2013;31:2942–62.PubMedCrossRef
26.
Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998;90:1371–88.PubMedCrossRef
27.
Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA. 2006;295:2727–41.PubMedCrossRef
28.
Oppong BA, King TA. Recommendations for women with lobular carcinoma in situ (LCIS). Oncology (Williston Park). 2011;25:1051–6.
29.
Simpson PT, Gale T, Fulford LG, Reis-Filho JS, Lakhani SR. The diagnosis and management of pre-invasive breast disease: pathology of atypical lobular hyperplasia and lobular carcinoma in situ. Breast Cancer Res. 2003;5:258–62.PubMedPubMedCentralCrossRef
30.
Moumen M, Chiche A, Cagnet S, Petit V, Raymond K, Faraldo MM, et al. The mammary myoepithelial cell. Int J Dev Biol. 2011;55:763–71.PubMedCrossRef
31.
32.
Bagaria SP, Shamonki J, Kinnaird M, Ray PS, Giuliano AE. The florid subtype of lobular carcinoma in situ: marker or precursor for invasive lobular carcinoma? Ann Surg Oncol. 2011;18:1845–51.PubMedCrossRef
33.
Shin SJ, Lal A, De Vries S, Suzuki J, Roy R, Hwang ES, et al. Florid lobular carcinoma in situ: molecular profiling and comparison to classic lobular carcinoma in situ and pleomorphic lobular carcinoma in situ. Hum Pathol. 2013;44:1998–2009.PubMedCrossRef
34.
Lopez-Garcia MA, Geyer FC, Lacroix-Triki M, Marchió C, Reis-Filho JS. Breast cancer precursors revisited: molecular features and progression pathways. Histopathology. 2010;57:171–92.PubMedCrossRef
35.
Middleton LP, Palacios DM, Bryant BR, Krebs P, Otis CN, Merino MJ. Pleomorphic lobular carcinoma: morphology, immunohistochemistry, and molecular analysis. Am J Surg Pathol. 2000;24:1650–6.PubMedCrossRef
36.
Chivukula M, Haynik DM, Brufsky A, Carter G, Dabbs DJ. Pleomorphic lobular carcinoma in situ (PLCIS) on breast core needle biopsies: clinical significance and immunoprofile. Am J Surg Pathol. 2008;32:1721–6.PubMedCrossRef
37.
Wick MR, Lillemoe TJ, Copland GT, Swanson PE, Manivel JC, Kiang DT. Gross cystic disease fluid protein-15 as a marker for breast cancer: immunohistochemical analysis of 690 human neoplasms and comparison with alpha-lactalbumin. Hum Pathol. 1989;20:281–7.PubMedCrossRef
38.
Bratthauer GL, Tavassoli FA. Lobular intraepithelial neoplasia: previously unexplored aspects assessed in 775 cases and their clinical implications. Virchows Arch. 2002;440:134–8.PubMedCrossRef
39.
Galimberti V, Monti S, Mastropasqua MG. DCIS and LCIS are confusing and outdated terms. They should be abandoned in favor of ductal intraepithelial neoplasia (DIN) and lobular intraepithelial neoplasia (LIN). Breast. 2013;22:431–5.PubMedCrossRef
40.
Downs-Kelly E, Bell D, Perkins GH, Sneige N, Middleton LP. Clinical implications of margin involvement by pleomorphic lobular carcinoma in situ. Arch Pathol Lab Med. 2011;135:737–43.PubMed
41.
Hu Z, Fan C, Oh DS, Marron JS, He X, Qaqish BF, et al. The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics. 2006;7:96.PubMedPubMedCentralCrossRef
42.
Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001;98:10869–74.PubMedPubMedCentralCrossRef
43.
Green AR, Young P, Krivinskas S, Rakha EA, Claire Paish E, Powe DG, et al. The expression of ERalpha, ERbeta and PR in lobular carcinoma in situ of the breast determined using laser microdissection and real-time PCR. Histopathology. 2009;54:419–27.PubMedCrossRef
44.
Mohsin SK, O’Connell P, Allred DC, Libby AL. Biomarker profile and genetic abnormalities in lobular carcinoma in situ. Breast Cancer Res Treat. 2005;90:249–56.PubMedCrossRef
45.
Querzoli P, Albonico G, Ferretti S, Rinaldi R, Beccati D, Corcione S, et al. Modulation of biomarkers in minimal breast carcinoma: a model for human breast carcinoma progression. Cancer. 1998;83:89–97.PubMedCrossRef
46.
Rudas M, Neumayer R, Gnant MF, Mittelböck M, Jakesz R, Reiner A. p53 protein expression, cell proliferation and steroid hormone receptors in ductal and lobular in situ carcinomas of the breast. Eur J Cancer. 1997;33:39–44.PubMedCrossRef
47.
Arpino G, Bardou VJ, Clark GM, Elledge RM. Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome. Breast Cancer Res. 2004;6:R149–56.PubMedPubMedCentralCrossRef
48.
Bharat A, Gao F, Margenthaler JA. Tumor characteristics and patient outcomes are similar between invasive lobular and mixed invasive ductal/lobular breast cancers but differ from pure invasive ductal breast cancers. Am J Surg. 2009;198:516–9.PubMedCrossRef
49.
Chen YY, Hwang ES, Roy R, DeVries S, Anderson J, Wa C, et al. Genetic and phenotypic characteristics of pleomorphic lobular carcinoma in situ of the breast. Am J Surg Pathol. 2009;33:1683–94.PubMedPubMedCentralCrossRef
50.
Cui X, Schiff R, Arpino G, Osborne CK, Lee AV. Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy. J Clin Oncol. 2005;23:7721–35.PubMedCrossRef
51.
Hopp TA, Weiss HL, Hilsenbeck SG, Cui Y, Allred DC, Horwitz KB, et al. Breast cancer patients with progesterone receptor PR-A-rich tumors have poorer disease-free survival rates. Clin Cancer Res. 2004;10:2751–60.PubMedCrossRef
52.
Wong H, Lau S, Cheung P, Wong TT, Parker A, Yau T, et al. Lobular breast cancers lack the inverse relationship between ER/PR status and cell growth rate characteristic of ductal cancers in two independent patient cohorts: implications for tumor biology and adjuvant therapy. BMC Cancer. 2014;14:826.PubMedPubMedCentralCrossRef
53.
Murphy LC, Leygue E. The role of estrogen receptor-beta in breast cancer. Semin Reprod Med. 2012;30:5–13.PubMedCrossRef
54.
Paech K, Webb P, Kuiper GG, Nilsson S, Gustafsson J, Kushner PJ, et al. Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites. Science. 1997;277:1508–10.PubMedCrossRef
55.
Huang B, Omoto Y, Iwase H, Yamashita H, Toyama T, Coombes RC, et al. Differential expression of estrogen receptor alpha, beta1, and beta2 in lobular and ductal breast cancer. Proc Natl Acad Sci U S A. 2014;111:1933–8.PubMedPubMedCentralCrossRef
56.
Nonni A, Zagouri F, Sergentanis TN, Lazaris AC, Patsouris ES, Zografos GC. Immunohistochemical expression of estrogen receptors alpha and beta in lobular neoplasia. Virchows Arch. 2007;451:893–7.PubMedCrossRef
57.
Figueroa-Magalhães MC. Jelovac D1, Connolly RM1, Wolff AC. Treatment of HER2-positive breast cancer. Breast. 2014;23:128–36.PubMedCrossRef
58.
Urruticoechea A, Smith IE, Dowsett M. Proliferation marker Ki-67 in early breast cancer. J Clin Oncol. 2005;23:7212–20.PubMedCrossRef
59.
Vincent-Salomon A, Hajage D, Rouquette A, Cédenot A, Gruel N, Alran S, et al. High Ki67 expression is a risk marker of invasive relapse for classical lobular carcinoma in situ patients. Breast. 2012;21:380–3.PubMedCrossRef
60.
61.
Andrade VP, Morrogh M, Qin LX, Olvera N, Giri D, Muhsen S, et al. Gene expression profiling of lobular carcinoma in situ reveals candidate precursor genes for invasion. Mol Oncol. 2015;9:772–82.PubMedCrossRef
62.
Tazaki E, Shishido-Hara Y, Mizutani N, Nomura S, Isaka H, Ito H, et al. Histopathologcial and clonal study of combined lobular and ductal carcinoma of the breast. Pathol Int. 2013;63:297–304.PubMedPubMedCentralCrossRef
63.
Abdel-Fatah TM, Powe DG, Hodi Z, Lee AH, Reis-Filho JS, Ellis IO. High frequency of coexistence of columnar cell lesions, lobular neoplasia, and low grade ductal carcinoma in situ with invasive tubular carcinoma and invasive lobular carcinoma. Am J Surg Pathol. 2007;31:417–26.PubMedCrossRef
64.
Abdel-Fatah TM, Powe DG, Hodi Z, Reis-Filho JS, Lee AH, Ellis IO. Morphologic and molecular evolutionary pathways of low nuclear grade invasive breast cancers and their putative precursor lesions: further evidence to support the concept of low nuclear grade breast neoplasia family. Am J Surg Pathol. 2008;32:513–23.PubMedCrossRef
65.
Hungermann D, Schmidt H, Natrajan R, Tidow N, Poos K, Reis-Filho JS, et al. Influence of whole arm loss of chromosome 16q on gene expression patterns in oestrogen receptor-positive, invasive breast cancer. J Pathol. 2011;224:517–28.PubMedCrossRef
66.
Stacher E, Boldt V, Leibl S, Halbwedl I, Popper HH, Ullmann R, et al. Chromosomal aberrations as detected by array comparative genomic hybridization in early low-grade intraepithelial neoplasias of the breast. Histopathology. 2011;59:549–55.PubMedCrossRef
67.
King TA, Sakr RA, Muhsen S, Andrade VP, Giri D, Van Zee KJ, et al. Is there a low-grade precursor pathway in breast cancer? Ann Surg Oncol. 2012;19:1115–21.PubMedCrossRef
68.
Green AR, Krivinskas S, Young P, Rakha EA, Paish EC, Powe DG, et al. Loss of expression of chromosome 16q genes DPEP1 and CTCF in lobular carcinoma in situ of the breast. Breast Cancer Res Treat. 2009;113:59–66.PubMedCrossRef
69.
Foschini MP, Righi A, Cucchi MC, Ragazzini T, Merelli S, Santeramo B, et al. The impact of large sections and 3D technique on the study of lobular in situ and invasive carcinoma of the breast. Virchows Arch. 2006;448:256–61.PubMedCrossRef
70.
Claus EB, Risch N, Thompson WD, Carter D. Relationship between breast histopathology and family history of breast cancer. Cancer. 1993;71:147–53.PubMedCrossRef
71.
Petridis C, Shinomiya I, Kohut K, Gorman P, Caneppele M, Shah V, et al. Germline CDH1 mutations in bilateral lobular carcinoma in situ. Br J Cancer. 2014;110:1053–7.PubMedCrossRef
72.
Kluijt I, Siemerink EJ, Ausems MG, van Os TA, de Jong D, Simões-Correia J, et al. CDH1-related hereditary diffuse gastric cancer syndrome: clinical variations and implications for counseling. Int J Cancer. 2012;131:367–76.PubMedCrossRef
73.
Sawyer E, Roylance R, Petridis C, Brook MN, Nowinski S, Papouli E, et al. Genetic predisposition to in situ and invasive lobular carcinoma of the breast. PLoS Genet. 2014;10, e1004285.PubMedPubMedCentralCrossRef
74.
Michailidou K, Hall P, Gonzalez-Neira A, Ghoussaini M, Dennis J, Milne RL, et al. Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nat Genet. 2013;45:353–61.PubMedPubMedCentralCrossRef
75.
76.
77.
Morrogh M, Andrade VP, Giri D, Sakr RA, Paik W, Qin LX, et al. Cadherin-catenin complex dissociation in lobular neoplasia of the breast. Breast Cancer Res Treat. 2012;132:641–52.PubMedCrossRef
78.
Cao D, Polyak K, Halushka MK, Nassar H, Kouprina N, Iacobuzio-Donahue C, et al. Serial analysis of gene expression of lobular carcinoma in situ identifies down regulation of claudin 4 and overexpression of matrix metalloproteinase 9. Breast Cancer Res. 2008;10:R91.PubMedPubMedCentralCrossRef
79.
Aigner K, Dampier B, Descovich L, Mikula M, Sultan A, Schreiber M, et al. The transcription factor ZEB1 (deltaEF1) promotes tumour cell dedifferentiation by repressing master regulators of epithelial polarity. Oncogene. 2007;26:6979–88.PubMedPubMedCentralCrossRef
80.
Aigner K, Descovich L, Mikula M, Sultan A, Dampier B, Bonné S, et al. The transcription factor ZEB1 (deltaEF1) represses Plakophilin 3 during human cancer progression. FEBS Lett. 2007;581:1617–24.PubMedPubMedCentralCrossRef
81.
Fackler MJ, McVeigh M, Evron E, Garrett E, Mehrotra J, Polyak K, et al. DNA methylation of RASSF1A, HIN-1, RAR-beta, Cyclin D2 and Twist in in situ and invasive lobular breast carcinoma. Int J Cancer. 2003;107:970–5.PubMedCrossRef
82.
Anastasiadis PZ, Reynolds AB. Regulation of Rho GTPases by p120-catenin. Curr Opin Cell Biol. 2001;13:604–10.PubMedCrossRef
83.
Shibata T, Kokubu A, Sekine S, Kanai Y, Hirohashi S. Cytoplasmic p120ctn regulates the invasive phenotypes of E-cadherin-deficient breast cancer. Am J Pathol. 2004;164:2269–78.PubMedPubMedCentralCrossRef
84.
Zou D, Yoon HS, Anjomshoaa A, Perez D, Fukuzawa R, Guilford P, et al. Increased levels of active c-Src distinguish invasive from in situ lobular lesions. Breast Cancer Res. 2009;11:R45.PubMedPubMedCentralCrossRef
85.
Viacava P, Naccarato AG, Collecchi P, Ménard S, Castronovo V, Bevilacqua G. The spectrum of 67-kD laminin receptor expression in breast carcinoma progression. J Pathol. 1997;182:36–44.PubMedCrossRef
86.
Ang DC, Warrick AL, Shilling A, Beadling C, Corless CL, Troxell ML. Frequent phosphatidylinositol-3-kinase mutations in proliferative breast lesions. Mod Pathol. 2014;27:740–50.PubMedCrossRef
87.
88.
Irby RB, Yeatman TJ. Role of Src expression and activation in human cancer. Oncogene. 2000;19:5636–42.PubMedCrossRef
89.
Bratthauer GL, Strauss BL, Tavassoli FA. STAT 5a expression in various lesions of the breast. Virchows Arch. 2006;448:165–71.PubMedCrossRef
90.
91.
Haricharan S, Dong J, Hein S, Reddy JP, Du Z, Toneff M, et al. Mechanism and preclinical prevention of increased breast cancer risk caused by pregnancy. Elife. 2013;2, e00996.PubMedPubMedCentralCrossRef
92.
Tran-Thanh D, Arneson NC, Pintilie M, Deliallisi A, Warren KS, Bane A, et al. Amplification of the prolactin receptor gene in mammary lobular neoplasia. Breast Cancer Res Treat. 2011;128:31–40.PubMedCrossRef
93.
Bratthauer GL, Strauss BL, Barner R. Reversed expression of the JAK/STAT pathway related proteins prolactin receptor and STAT5a in normal and abnormal breast epithelial cells. Breast Cancer (Auckl). 2008;1:7–14.
94.
Perrone G, Zagami M, Altomare V, Battista C, Morini S, Rabitti C. COX-2 localization within plasma membrane caveolae-like structures in human lobular intraepithelial neoplasia of the breast. Virchows Arch. 2007;451:1039–45.PubMedCrossRef
95.
Perrone G, Zagami M, Santini D, Vincenzi B, Gullotta G, Morini S, et al. COX-2 expression in lobular in situ neoplasia of the breast: correlation with histopathological grading system according to the Tavassoli classification. Histopathology. 2007;51:33–9.PubMedCrossRef
96.
97.
Vos CB, Cleton-Jansen AM, Berx G, de Leeuw WJ, ter Haar NT, van Roy F, et al. E-cadherin inactivation in lobular carcinoma in situ of the breast: an early event in tumorigenesis. Br J Cancer. 1997;76:1131–3.PubMedPubMedCentralCrossRef
98.
Palacios J, Sarrió D, García-Macias MC, Bryant B, Sobel ME, Merino MJ. Frequent E-cadherin gene inactivation by loss of heterozygosity in pleomorphic lobular carcinoma of the breast. Mod Pathol. 2003;16:674–8.PubMedCrossRef
99.
Sarrió D, Moreno-Bueno G, Hardisson D, Sánchez-Estévez C, Guo M, Herman JG, et al. Epigenetic and genetic alterations of APC and CDH1 genes in lobular breast cancer: relationships with abnormal E-cadherin and catenin expression and microsatellite instability. Int J Cancer. 2003;106:208–15.PubMedCrossRef
100.
Mastracci TL, Tjan S, Bane AL, O’Malley FP, Andrulis IL. E-cadherin alterations in atypical lobular hyperplasia and lobular carcinoma in situ of the breast. Mod Pathol. 2005;18:741–51.PubMedCrossRef
101.
Rieger-Christ KM, Pezza JA, Dugan JM, Braasch JW, Hughes KS, Summerhayes IC. Disparate E-cadherin mutations in LCIS and associated invasive breast carcinomas. Mol Pathol. 2001;54:91–7.PubMedPubMedCentralCrossRef
Metadata
Title
Molecular drivers of lobular carcinoma in situ
Authors
Greg J. Logan
David J. Dabbs
Peter C. Lucas
Rachel C. Jankowitz
Daniel D. Brown
Beth Z. Clark
Steffi Oesterreich
Priscilla F. McAuliffe
Publication date
01-12-2015
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 1/2015
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/s13058-015-0580-5

Other articles of this Issue 1/2015

Breast Cancer Research 1/2015 Go to the issue

Research article

ALK alteration is a frequent event in aggressive breast cancers

Research article

A case–control analysis of oral contraceptive use and breast cancer subtypes in the African American Breast Cancer Epidemiology and Risk Consortium

Research article

Leptin produced by obese adipose stromal/stem cells enhances proliferation and metastasis of estrogen receptor positive breast cancers

Research article

Expression profiling of in vivo ductal carcinoma in situ progression models identified B cell lymphoma-9 as a molecular driver of breast cancer invasion

Letter

Longer term effects of the Angelina Jolie effect: increased risk-reducing mastectomy rates in BRCA carriers and other high-risk women

Research article

Quantitative assessment of background parenchymal enhancement in breast MRI predicts response to risk-reducing salpingo-oophorectomy: preliminary evaluation in a cohort of BRCA1/2 mutation carriers
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits